Manténgase sano!

A small clinical trial suggests that a duo of drugs can extend survival for people battling advanced kidney cancer.

Researchers at Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., developed the new regimen, a combination of pazopanib (Votrient) and bevacizumab (Avastin).

Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current method of intravenous delivery, a new study finds.

The results of the new trial using injected Opdivo (nivolumab) could free up time and money for cancer patients, the research team said.

"The burden of treatment...

Dropping a load of pounds through weight-loss surgery can significantly decrease your risk of developing or dying from cancer, according to three new studies.

Obese folks who underwent bariatric surgery were at least two times less likely to develop certain types of cancer and more than three times less likely to die of cancer than heavy people who didn't get the procedure, according to a...

The use of immunotherapy and/or targeted drugs revolutionized the treatment of many cancers, but some people grow resistant to immunotherapy drugs and relapse as a result.

For cases of advanced kidney cancer, a new drug in combination with an existing therapy appears to extend surviv...

The early months of the COVID-19 pandemic kept millions of Americans away from routine cancer screenings. Now a new study finds that many U.S. screening programs were still not back to normal by 2021.

The study, of more than 700 cancer facilities nationwide, found that in January 2021 - a year after COVID's emergence in the United States - most still had not recovered their pre-pandemic s...

People with cancer may be at increased risk for a rare neurological disorder called Guillain-Barré syndrome, new research has found.

"Previous studies have suggested there may be a link between cancer and Guillain-Barré syndrome, but just how often people develop